Prosomnus Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Prosomnus Inc (OSA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Prosomnus Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 32M vs 121,233M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+12.3% annualized vs trailing 12 months), vs decelerating (-31.1%) for its tracked peer group.
- Growth: Prosomnus Inc generated 34.4% revenue growth year over year in Q2 2024, vs 6.3% for its competitors combined.
- Profitability: Its -167.0% net margin compares with 13.3% for the peer group.
- Peer revenue share: Prosomnus Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
OSA Sales vs. its Competitors, Q2 2024
Prosomnus Inc reported revenue growth of 34.44 % year on year in Q2 2024, above its competitors' combined revenue growth of 6.27 %.
With a net margin of -166.97 %, Prosomnus Inc reported lower profitability than its competitors (13.30 %).
Prosomnus Inc generated 0.04 % of the combined sales of its peer group, up from 0.03 % a year earlier.
API endpoints for this dataset
Prosomnus Inc vs. its Competitors, Q2 2024
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Prosomnus Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Prosomnus Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Prosomnus Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Prosomnus Inc's competitor groups requires a Commercial License.
For context: the Medical Equipment & Supplies industry grew revenue 14.4% year over year, combined, vs 34.4% for Prosomnus Inc. Prosomnus Inc's share of combined industry revenue moved from 0.01% to 0.01%, a gain of 0.00 percentage points.
Prosomnus Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Prosomnus Inc | No | Yes | Yes | Yes |
| Competitors combined (19) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
OSA Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Pro dex Inc | 282.9% | Outperformed |
| 2 | Edwards Lifesciences Corporation | 282.9% | Outperformed |
| 3 | Neurometrix Inc | 282.9% | Outperformed |
| 4 | Penumbra Inc | 282.9% | Outperformed |
| 5 | Electrocore Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Prosomnus Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Prosomnus Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Prosomnus Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Prosomnus Inc |
8.17 | 32.39 |
 Medtronic Plc |
131,298.67 | 37,542.00 |
 Stryker Corp |
123,250.19 | 26,300.00 |
 Boston Scientific Corporation |
65,441.64 | 21,070.00 |
 Edwards Lifesciences Corporation |
61,595.26 | 6,512.50 |
 Resmed Inc |
34,246.55 | 5,743.16 |
| SUBTOTAL | 463,592.22 | 122,491.45 |
Sign in to see all competitors of Prosomnus Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Prosomnus Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Prosomnus Inc's Competitors Named by the Company
Competitive relationships identified from Prosomnus Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Inspire Medical (Inspire) | Company report | 85% |
| Resmed Inc | Company report | 85% |
| Inspire Medical Systems inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Prosomnus Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Prosomnus Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Medtronic Plc | CARDIOVASCULAR 38.34 % |
| Stryker Corp | MedSurg and Neurotechnology 56.20 % |
| Boston Scientific Corporation | Cardiovascular 66.29 % |
| Edwards Lifesciences Corporation | United States 58.74 % |
| Resmed Inc | Devices 49.96 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Prosomnus Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Prosomnus Inc | 8 | - | - |
| Medtronic Plc | 131,299 | 395,179 | 55,463 |
| Stryker Corp | 123,250 | 469,643 | 64,696 |
| Boston Scientific Corporation | 65,442 | 357,119 | 59,220 |
| Edwards Lifesciences Corporation | 61,595 | 407,031 | 62,725 |
| Resmed Inc | 34,247 | 505,116 | 140,120 |
| PEERS TOTAL | 463,584 | 384,888 | 50,607 |
Prosomnus Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Medtronic Plc | United States 49.83 % |
| Stryker Corp | United States 75.92 % |
| Boston Scientific Corporation | United States 64.40 % |
| Resmed Inc | Combined Europe Asia and other markets 31.05 % |
| Penumbra Inc | United States 79.06 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Prosomnus Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 48.31 % | 46.85 % (avg) | +1.5 pp |
| Operating Margin | -40.96 % | industry median | -28.9 pp |
| EBITDA Margin | -73.31 % | -6.45 % (avg) | -66.9 pp |
| Capital Intensity (Capex / Revenue) | 2.13 % | 7.11 % (avg) | -5.0 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Prosomnus Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 37.2x | - |
| EV / EBITDA | - | 17.5x | - |
| P/B | -0.2x | 4.7x | -5.0x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | - | -6.49 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Prosomnus Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 2.13 % vs industry average 7.11 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Prosomnus Inc's dedicated Suppliers and Customers pages, not here.
Prosomnus Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Prosomnus Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Prosomnus Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+12.3% annualized vs trailing 12 months).
Weaknesses
- Operating margin 28.9 points below the industry median.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-31.1% annualized).
Methodology: see Methodology: SWOT Analysis.
Prosomnus Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Prosomnus Inc | 0.34 | 0.69 | - |
| Medtronic Plc | 0.15 | 2.10 | 0.57 |
| Stryker Corp | 0.50 | 2.08 | 0.65 |
| Boston Scientific Corporation | 0.23 | 1.50 | 0.46 |
| Edwards Lifesciences Corporation | 1.74 | 4.14 | 0.06 |
| Resmed Inc | 1.05 | 3.03 | 0.10 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Prosomnus Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Prosomnus Inc | Q2 2024 | +34.4 % | - |
| Medtronic Plc | Q2 2026 | +13.7 % | +41.3 % |
| Stryker Corp | Q3 2026 | +7.6 % | -12.3 % |
| Boston Scientific Corporation | Q3 2026 | +1.4 % | -23.2 % |
| Edwards Lifesciences Corporation | Q2 2026 | +13.7 % | -27.2 % |
| Resmed Inc | Q3 2026 | +8.7 % | +20.0 % |
| PEERS TOTAL | +6.4 % | +68.5 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Prosomnus Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Prosomnus Inc | Q2 2024 | +42.3 % | +69.5 % |
| Medtronic Plc | Q2 2026 | +13.8 % | -0.2 % |
| Stryker Corp | Q3 2026 | +3.0 % | +26.7 % |
| Boston Scientific Corporation | Q3 2026 | +12.3 % | -0.6 % |
| Edwards Lifesciences Corporation | Q2 2026 | +14.1 % | +35.7 % |
| Resmed Inc | Q3 2026 | +5.1 % | +13.4 % |
Prosomnus Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Prosomnus Inc | - | - | - |
| Medtronic Plc | 5.71% | 6.46% | 10.64% |
| Stryker Corp | 7.66% | 8.63% | 15.61% |
| Boston Scientific Corporation | 7.82% | 9.14% | 13.75% |
| Edwards Lifesciences Corporation | 7.41% | 8.39% | 9.65% |
| Resmed Inc | 18.67% | 21.10% | 25.50% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Prosomnus Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Prosomnus Inc | - | 0.25 |
| Medtronic Plc | 300.50 | 3.50 |
| Stryker Corp | 34.12 | 4.69 |
| Boston Scientific Corporation | 19.12 | 3.11 |
| Edwards Lifesciences Corporation | 61.39 | 9.46 |
| Resmed Inc | 21.77 | 5.96 |
| PEERS AVERAGE | 28.85 | 3.78 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.